FMT Capsule
Broad-spectrum gut microbiome restoration
PreclinicalPlanned for late 2026 launch
Key Facts
Indication
Broad-spectrum gut microbiome restoration
Phase
Preclinical
Status
Planned for late 2026 launch
Company
About BiomeBank
Australian biotech leveraging co‑cultured gut microbiome consortia to deliver regulated, scalable therapies for C. and and ulcerative colitis.
View full company profile